Management Credibility Analysis
Upcoming Catalysts
Verified event feedCompany profile
No description available
- Chief executive
- Not disclosed
- Headquarters
- 325 BINNEY STREET, CAMBRIDGE, MA
- Founded
- Not disclosed
📈 Company Timeline
Moderna, Inc. reported A director or senior management change or compensation event
Moderna, Inc. filed an 8-K covering a director or senior management change or compensation event, Regulation FD disclosure, supporting financial statements or exhibits.
Moderna, Inc. reported A material agreement
Moderna, Inc. filed an 8-K covering a material agreement, a material financing obligation, an unregistered sale of shares, another company event, supporting financial statements or exhibits.
Large-holder ownership filing
A holder reported or amended a beneficial ownership position of more than 5% in Moderna, Inc..
Large-holder ownership filing
A holder reported or amended a beneficial ownership position of more than 5% in Moderna, Inc..
Moderna, Inc. filed Form 10-Q
Moderna, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
Capital Structure & Financial Position
Financial strength and liquidity analysisSource: SEC EDGAR company facts (opens in a new tab) Balance sheet dated
Peer Comparison - Health Care
| Company | Price | Market Cap |
|---|---|---|
| LLY - Eli Lilly and Company |
$1,276.13
Yahoo Finance |
$1.20T |
| JNJ - Johnson & Johnson |
$256.74
Yahoo Finance |
$618.71B |
| ABBV - AbbVie Inc. |
$284.80
Yahoo Finance |
$503.28B |
| UNH - UnitedHealth Group Incorporated |
$418.43
Yahoo Finance |
$375.58B |
| MRK - Merck & Co., Inc. |
$148.55
Yahoo Finance |
$366.50B |
📋 Corporate Actions
Recent and upcoming corporate eventsFinancials
Financial statements and key metrics analysis| Quarter | Revenue (USD) | Operating income | Net income | Diluted EPS (USD) | Filed |
|---|---|---|---|---|---|
| Q2 2026 | $145.00M | −$815.00M | −$782.00M | −$1.97 | 10-Q · 31 Jul 2026 |
| Q1 2026 | $389.00M | −$1.39B | −$1.34B | −$3.40 | 10-Q · 1 May 2026 |
| Q4 2025 | $678.00M | −$857.00M | −$826.00M | Unavailable | 10-K · 20 Feb 2026 |
| Q3 2025 | $1.02B | −$260.00M | −$200.00M | −$0.51 | 10-Q · 6 Nov 2025 |
| Q2 2025 | $142.00M | −$907.00M | −$825.00M | −$2.13 | 10-Q · 1 Aug 2025 |
| Q1 2025 | $108.00M | −$1.05B | −$971.00M | −$2.52 | 10-Q · 1 May 2025 |
Analyst Consensus
Source: Nasdaq analyst research (opens in a new tab) Retrieved Targets range 45.00–220.00 Ratings are third-party opinions, not advice.
💰 Upcoming Dividends
Next dividend paymentsGuidance Evolution
💼 Director Transactions
Recent insider activityTop Shareholders
Source: Nasdaq institutional holdings (opens in a new tab) Observed · 9 hours ago